CancerDrs

Breast Cancer clinical trials in Mississippi

7 actively recruiting breast cancer trials at 10 sites across Mississippi.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Mississippi:
  • Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
  • Baptist Cancer Center-Grenada — Grenada, Mississippi
  • University of Mississippi Medical Center — Jackson, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Mississippi:
  • Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
  • Baptist Cancer Center-Grenada — Grenada, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Desoto — Southhaven, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…

Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Mississippi:
  • Baptist Clinical Research Institution — Oxford, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Mississippi:
  • Research Site — Hattiesburg, Mississippi
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Mississippi:
  • Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
  • Baptist Cancer Center-Grenada — Grenada, Mississippi
  • Gulfport Memorial Hospital — Gulfport, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
View on ClinicalTrials.gov →
NA Recruiting Network

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using marke…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03723928
Sites in Mississippi:
  • Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
  • Baptist Cancer Center-Grenada — Grenada, Mississippi
  • Gulfport Memorial Hospital — Gulfport, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
View on ClinicalTrials.gov →
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Mississippi:
  • Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
  • Baptist Cancer Center-Grenada — Grenada, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Desoto — Southaven, Mississippi
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15